Literature DB >> 6602761

Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells.

A Rey, B Klein, D Zagury, C Thierry, B Serrou.   

Abstract

Interleukin-2 (IL-2) activity production by stimulated peripheral blood lymphocytes (PBL) from solid tumor bearing cancer patients was lower than in normal subjects. Natural-killer (NK) cell activity in the PBL of cancer patients was very significantly correlated to IL-2 activity production (P less than 0.001). These results might suggest a central role for IL-2 in the immune dysfunctions in cancer patients, and the possible use of IL-2 as an immunological response modifier in these patients.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6602761     DOI： 10.1016/0165-2478(83)90101-3

Source DB:  PubMed          Journal:  Immunol Lett        ISSN： 0165-2478            Impact factor:   3.685


  8 in total

1.  Observation of activity of IL-2 produced by mononuclear cells in tumor draining lymph-node.

Authors:  J M Fang; A H Bi
Journal:  J Tongji Med Univ       Date:  1989

2.  Biologic characteristics of an immunosuppressive factor derived from a human lung cancer cell line.

Authors:  R D Wang; Z C Chen; Y Luo; Z H Feng
Journal:  J Tongji Med Univ       Date:  1989

3.  Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas.

Authors:  U Elsässer-Beile; S von Kleist; R Fischer; M Martin; U Wetterauer; H Gallati; J S Mönting
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Effect of tumor-derived immunosuppressive factor(s) on interleukin 2 and on expression of interleukin 2 receptor.

Authors:  R D Wang; Y Luo; Z H Feng; Z C Chen
Journal:  J Tongji Med Univ       Date:  1990

5.  Cytokine production in whole blood cell cultures of patients undergoing therapy with biological response modifiers or 5-fluorouracil.

Authors:  U Elsässer-Beile; S von Kleist; A Lindenthal; R Birken; H Gallati; J S Mönting
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

6.  Interleukin-2 production by persons with the generalized lymphadenopathy syndrome or the acquired immune deficiency syndrome.

Authors:  C H Kirkpatrick; K C Davis; C R Horsburgh; D L Cohn; K Penley; F N Judson
Journal:  J Clin Immunol       Date:  1985-01       Impact factor: 8.317

7.  Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome.

Authors:  B K Pedersen; P Oxholm; R Manthorpe; V Andersen
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

8.  Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages.

Authors:  U Elsässer-Beile; S von Kleist; W Sauther; H Gallati; J S Mönting
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.